← All stocks

GENELUX Corp

GNLX Net selling

CIK 0001231457 #4219 in the set updated 17 Sep 2026

Bought (12 mo)

$0.00

out of their own pocket, the only kind of buying there is

Sold (12 mo)

$368.04K

$108.77K on a plan · $0.00 straight out of an exercise

Sold at will

$259.28K

22 of 25 sales

Net

−$368.04K

−$259.28K against sales at will

By person

12 insiders · 25 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Zindrick Thomas

President and CEO

—

$141.91K (5)

−$141.91K

1,226,427

2.71%

$3.38M

+2,093%

Thomas John

Director

—

$108.77K (3) scheduled

−$108.77K

501,193

1.11%

$1.38M

−0.9%

Cappello Joseph

Chief Technical Officer

—

$39.25K (5)

−$39.25K

318,480

0.7039%

$876.81K

+1,420%

Yu Yong

Chief Scientific Officer

—

$37.80K (5)

−$37.80K

258,688

0.5717%

$712.19K

+1,408%

Smither John W

Director

—

$34.90K (1)

−$34.90K

91,403

0.2020%

$251.64K

+73.4%

Smalling Ralph

Head of Regulatory

—

$5.42K (6)

−$5.42K

67,611

0.1494%

$186.14K

+259.0%

Pulisic Matthew

Chief Financial Officer

—

278,906

0.6164%

$767.86K

—

Groen Eric

General Counsel

—

233,957

0.5171%

$644.11K

—

Mirabelli Mary

Director

—

102,693

0.2270%

$282.72K

+97.5%

Tyree James L

Director

—

96,483

0.2132%

$265.63K

+95.9%

Zak Lourie S.

Chief Financial Officer

—

82,452

0.1822%

$227.00K

+92.2%

Ryder Sean

General Counsel

—

47,621

0.1053%

$131.11K

+145.6%

Individual transactions

Nothing of that kind in this period.

What was left out

Form 4 filings counted 33

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 0

Sales on a Rule 10b5-1 plan 3

Sales straight out of an exercise 0

Sales at will 22

Transactions with no price 0

Shares from compensation/vesting 1,651,259

History held since 30 Jan 2023